Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmascience Canada is Thrilled to Launch (PR)pms-Teriflunomide
Details : Aubagio-Generic (teriflunomide) is an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase. It is indicated for the treatment of patients with relapsing remitting multiple sclerosis.
Product Name : pms-Teriflunomide
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.
Product Name : Myinfla
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 22, 2021
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study
Details : Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.
Product Name : Myinfla
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Colchicine Reduces the Risk of COVID-19-related Complications
Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Product Name : Myinfla
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 23, 2021
Lead Product(s) : Colchicine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Colchicine Shows Promise as a Treatment for at-home COVID-19 Patients
Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Product Name : Myinfla
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 29, 2020
Lead Product(s) : Colchicine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first of these sub analyses simultaneously published in the European Heart Journal reveals that early initiation of low-dose colchicine within the first 3 days after MI significantly reduces the risk of ischemic CV events by 48% as vs placebo on top ...
Product Name : Myinfla
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Product Name : Myinfla
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 30, 2020
Lead Product(s) : Colchicine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Montreal Heart Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cholestyramine
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2019
Lead Product(s) : Cholestyramine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Decitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Royal DSM | MDEIE Ministry, Québec Government | INRS-Institut Armand Frappier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 26, 2012
Lead Product(s) : Decitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Royal DSM | MDEIE Ministry, Québec Government | INRS-Institut Armand Frappier
Deal Size : Inapplicable
Deal Type : Inapplicable